Holen Sie sich die Stockscreener-App
40.42
6.82%
2.58
Handel nachbörslich:
40.49
0.07
+0.17%
Schlusskurs vom Vortag:
$37.84
Offen:
$36.6
24-Stunden-Volumen:
9.46M
Relative Volume:
2.40
Marktkapitalisierung:
$17.47B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
17.60
EPS:
2.297
Netto-Cashflow:
$827.02M
1W Leistung:
+10.23%
1M Leistung:
+12.06%
6M Leistung:
+22.48%
1J Leistung:
+46.77%
1-Tages-Spanne:
$36.03
$41.00
1-Wochen-Bereich:
$36.03
$41.00
52-Wochen-Spanne:
$24.05
$41.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
40.42 | 16.36B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.00 | 107.10B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.19 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.35 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.88 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma’s Q3 2025 Earnings Call Highlights - TipRanks
Royalty Pharma (RPRX) Earnings Soar 52% as Margin Surge Challenges Bearish Narratives - Yahoo Finance
Is Royalty Pharma plc stock supported by strong fundamentalsJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - fcp.pa.gov.br
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar
Is Royalty Pharma plc (RPD) stock undervalued historicallyJuly 2025 Opening Moves & Target Return Focused Stock Picks - fcp.pa.gov.br
Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025 - MarketScreener
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma Q3 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma Raises Earnings Outlook After Beating Estimates - Finimize
Royalty Pharma plc Reports Earnings Results for the Third Quarter Ended September 30, 2025 - MarketScreener
Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: Royalty Pharma Q3 2025 reports robust growth - Investing.com
Royalty Pharma plc SEC 10-Q Report - TradingView
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Royalty Pharma Q3 Profit Falls - Nasdaq
Royalty Pharma Reports Third Quarter 2025 Results - TradingView
Earnings Flash (RPRX) Royalty Pharma plc Reports Q3 Revenue $609.0M - MarketScreener
Press Release: Royalty Pharma Reports Third Quarter 2025 Results - 富途牛牛
Historical volatility pattern of Royalty Pharma plc visualizedJuly 2025 Outlook & Weekly Top Gainers Alerts - newser.com
Homestead Advisers Corp Purchases 8,300 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Why analysts remain bullish on Royalty Pharma plc stock2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Is Royalty Pharma plc (RPD) stock attractive post correctionWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveTrade Risk Assessment & Weekly High Momentum Picks - newser.com
Can Royalty Pharma plc stock rebound after recent weaknessM&A Rumor & Technical Entry and Exit Alerts - newser.com
Top chart patterns to watch in Royalty Pharma plcDay Trade & Real-Time Market Trend Scan - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targets2025 Price Momentum & Reliable Volume Spike Trade Alerts - newser.com
Royalty Pharma stock hits 52-week high at 38.01 USD By Investing.com - Investing.com Nigeria
Is Royalty Pharma plc reversing from oversold territoryDividend Hike & Low Risk Investment Opportunities - newser.com
What’s the recovery path for long term holders of Royalty Pharma plc2025 Technical Overview & Reliable Volume Spike Alerts - newser.com
How Royalty Pharma plc (RPD) stock performs in easing cycles2025 Analyst Calls & Weekly Watchlist of Top Performers - newser.com
Will Royalty Pharma plc (RPD) stock maintain strong growth - newser.com
Royalty Pharma acquires AMVUTTRA royalty interest for $310 million By Investing.com - Investing.com Nigeria
What indicators show strength in Royalty Pharma plcWeekly Profit Report & Weekly Breakout Opportunity Watchlist - newser.com
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - MSN
Royalty Pharma Plc Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Royalty Pharma stock hits 52-week high at 38.01 USD - Investing.com
Royalty Pharma acquires AMVUTTRA royalty interest for $310 million - Investing.com
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Royalty Pharma acquires AMVUTTRA royalty for $310 million - StreetInsider
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Using Python tools to backtest Royalty Pharma plc strategies2025 Volume Leaders & Fast Gain Swing Trade Alerts - newser.com
Corton Capital Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Applying chart zones and confluence areas to Royalty Pharma plcMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Royalty Pharma PLC $RPRX Shares Purchased by Strs Ohio - MarketBeat
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings - Yahoo! Finance UK
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's 3rd Largest Position - MarketBeat
Tredje AP fonden Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock a top momentum playWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
What the charts say about Royalty Pharma plc today2025 Price Momentum & Scalable Portfolio Growth Methods - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next year2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.50%
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):